Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China
|
MSCI China Small-Cap
|
Hang Seng Index
|
Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

AbbVie

BeiGene has a total of three marketed proprietary products.

FAST NEWS: Beigene stock falls after Novartis terminates partnership

The latest: Cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Tuesday that Novartis (NOVN.SWX) will relinquish its rights to co-develop, produce and commercialize BeiGene’s esophagus cancer drug tislelizumab. Looking up: Novartis will provide…
September 20, 2023
BGNE.US
6160.HK
BeiGene was slapped with a patent lawsuit by U.S. rival AbbVie in June, and suffered another blow to its global ambitions in July when Novartis pulled out of a drug collaboration.

Sales success comes with side effects for drug maker BeiGene

The Chinese biotech’s product revenues surged nearly 82% in the second quarter, driven by forecast-beating sales of its core cancer drugs Key Takeaways: Global sales of BeiGene's anti-tumor drug zanubrutinib…
August 10, 2023
BGNE.US
6160.HK
China throws money in developing countries

PODCAST: Corruption at a major policy bank, and AbbVie sues an upstart drug maker

China Development Bank has become the target of the latest anti-corruption crackdown by China’s main graft buster. Will this affect China’s policy of lending big money to developing countries, and if so, what’s driving such a shift?
July 4, 2023

I-Mab gets new CEO after long search. Sale of the company coming next?

The drug developer filled an 18-month-long vacuum in its top position by appointing an industry veteran with a history of deal-making as its new CEO Key Takeaways: I-Mab has appointed…
June 28, 2023
IMAB.US

Recent Articles

BeiGene has a total of three marketed proprietary products.
September 20, 2023

FAST NEWS: Beigene stock falls after Novartis terminates partnership

BGNE.US
6160.HK
August 10, 2023

Sales success comes with side effects for drug maker BeiGene

BGNE.US
6160.HK
July 4, 2023

PODCAST: Corruption at a major policy bank, and AbbVie sues an upstart drug maker

June 28, 2023

I-Mab gets new CEO after long search. Sale of the company coming next?

IMAB.US

RELATED ARTICLES

  1. Everest makes mRNA vaccines
    March 25, 2025
    Everest Medicines drives growth with AI-powered mRNA pipeline
    1952.HK
  2. March 20, 2025
    A blockbuster cancer drug? TYK’s claims go under the microscope
    2410.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.